X

Sign up for Equitymaster's free daily newsletter, The 5 Minute WrapUp and get access to our latest Multibagger guide (2017 Edition) on picking money-making stocks.

This is an entirely free service. No payments are to be made.


Download Now Subscribe to our free daily e-letter, The 5 Minute WrapUp and get this complimentary report.
We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
Compare Sun Pharma with ALEMBIC LTD - Equitymaster
  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

SUN PHARMA vs ALEMBIC LTD - Comparison Results

SUN PHARMA    Change

Sun Pharma holds 3.7% share of the domestic pharma market (as per the latest ORG IMS MAT data) and has a strong presence in the lifestyle therapeutic segments. The company started focusing on the exports market in FY02, when it increased its stake to... More

ALEMBIC LTD 
   Change

Alembic Limited, in its 99 years of existence, has evolved from being a tincture manufacturer to one of the prominent indigenous pharma companies in India. It is among the top players in the macrolides (anti-infective) and anti-microbials (animal hea... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    SUN PHARMA ALEMBIC LTD SUN PHARMA/
ALEMBIC LTD
 
P/E (TTM) x 15.3 76.5 20.0% View Chart
P/BV x 3.6 2.8 126.7% View Chart
Dividend Yield % 0.2 0.4 53.9%  

Financials

 SUN PHARMA   ALEMBIC LTD
EQUITY SHARE DATA
    SUN PHARMA
Mar-16
ALEMBIC LTD
Mar-16
SUN PHARMA/
ALEMBIC LTD
5-Yr Chart
Click to enlarge
High Rs1,20153 2,274.1%   
Low Rs70629 2,410.9%   
Sales per share (Unadj.) Rs117.54.7 2,488.9%  
Earnings per share (Unadj.) Rs19.68.8 223.4%  
Cash flow per share (Unadj.) Rs23.89.0 264.4%  
Dividends per share (Unadj.) Rs1.000.15 666.7%  
Dividend yield (eoy) %0.10.4 28.7%  
Book value per share (Unadj.) Rs130.527.7 470.6%  
Shares outstanding (eoy) m2,406.60267.03 901.2%   
Bonus/Rights/Conversions ---  
Price / Sales ratio x8.18.7 93.3%   
Avg P/E ratio x48.74.7 1,040.0%  
P/CF ratio (eoy) x40.14.6 878.5%  
Price / Book Value ratio x7.31.5 493.6%  
Dividend payout %5.11.7 298.5%   
Avg Mkt Cap Rs m2,294,81310,962 20,935.1%   
No. of employees `00014.7NA-   
Total wages/salary Rs m47,971238 20,156.0%   
Avg. sales/employee Rs Th19,169.8NM-  
Avg. wages/employee Rs Th3,253.0NM-  
Avg. net profit/employee Rs Th3,197.9NM-  
INCOME DATA
Net Sales Rs m282,6971,260 22,430.9%  
Other income Rs m6,170264 2,338.8%   
Total revenues Rs m288,8671,524 18,953.3%   
Gross profit Rs m83,23983 100,530.1%  
Depreciation Rs m10,13561 16,506.8%   
Interest Rs m4,7690 1,589,633.3%   
Profit before tax Rs m74,505285 26,151.1%   
Minority Interest Rs m-11,1260-   
Prior Period Items Rs m-192,096 -0.9%   
Extraordinary Inc (Exp) Rs m-6,852-32 21,278.6%   
Tax Rs m9,3496 153,262.3%   
Profit after tax Rs m47,1592,343 2,012.9%  
Gross profit margin %29.46.6 448.2%  
Effective tax rate %12.52.1 586.1%   
Net profit margin %16.7185.9 9.0%  
BALANCE SHEET DATA
Current assets Rs m308,6461,689 18,276.0%   
Current liabilities Rs m132,477486 27,247.3%   
Net working cap to sales %62.395.4 65.3%  
Current ratio x2.33.5 67.1%  
Inventory Days Days83217 38.2%  
Debtors Days Days8881 108.3%  
Net fixed assets Rs m133,6061,624 8,226.5%   
Share capital Rs m2,407534 450.6%   
"Free" reserves Rs m266,9095,960 4,478.2%   
Net worth Rs m314,0427,404 4,241.6%   
Long term debt Rs m31,167104 29,882.4%   
Total assets Rs m542,1968,010 6,768.7%  
Interest coverage x16.6950.7 1.7%   
Debt to equity ratio x0.10 704.5%  
Sales to assets ratio x0.50.2 331.4%   
Return on assets %9.629.3 32.7%  
Return on equity %15.031.6 47.5%  
Return on capital %17.831.3 56.7%  
Exports to sales %14.02.9 475.5%   
Imports to sales %3.128.9 10.9%   
Exports (fob) Rs m39,57237 106,662.3%   
Imports (cif) Rs m8,882364 2,442.2%   
Fx inflow Rs m42,17137 113,668.5%   
Fx outflow Rs m21,583365 5,914.0%   
Net fx Rs m20,588-328 -6,280.0%   
CASH FLOW
From Operations Rs m67,694346 19,587.3%  
From Investments Rs m-44,549-48 93,590.5%  
From Financial Activity Rs m-19,243-301 6,393.1%  
Net Cashflow Rs m3,902-3 -130,050.0%  

Share Holding

Indian Promoters % 63.7 64.0 99.5%  
Foreign collaborators % 0.0 0.0 -  
Indian inst/Mut Fund % 5.1 0.2 2,565.0%  
FIIs % 23.0 9.7 237.1%  
ADR/GDR % 0.0 0.0 -  
Free float % 8.3 26.1 31.8%  
Shareholders   133,026 54,701 243.2%  
Pledged promoter(s) holding % 0.5 0.0 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare SUN PHARMA With:   TTK HEALTHCARE  UNICHEM LAB  CIPLA  ELDER PHARMA  SUVEN LIFE  

Compare SUN PHARMA With:   ACTAVIS (US)  MYLAN (US)  ADCOCK INGRAM (S. Africa)  TEVA PHARMA (Israel)  



Today's Market

Sensex Opens Higher; Realty & Pharma Stocks Lead(09:30 am)

Asian stock indices are trading mixed today. The Shanghai Composite is lower by 0.29% while the Hang Seng is even. The Nikkei 225 is trading higher by 0.46%.

Related Views on News

Sun Pharma: Bottomline Slips into the Red Amidst Challenging Environment (Quarterly Results Update - Detailed)

Aug 14, 2017

A challenging environment and one-time expense pushes Sun Pharma into a loss in the first quarter.

Sun Pharma: Price Erosion in US Impacts Growth (Quarterly Results Update - Detailed)

May 30, 2017

US markets decline while other geographies grow in the quarter.

Lupin: Bigger Challenges or Bigger Margin of Safety? (Quarterly Results Update - Detailed)

Aug 14, 2017

GST impact coupled with price erosion in US leads to lower profits for the quarter.

Dr Reddy's: US Pressure Continues to Haunt (Quarterly Results Update - Detailed)

Aug 8, 2017

Profits plunge due to higher raw material costs.

Biocon: Lower Licensing Income Leads to Muted Growth for the Quarter (Quarterly Results Update - Detailed)

Jun 23, 2017

Net Profit lower due to exceptional items in the previous year.

More Views on News

Most Popular

This Small Cap Can Drive Chinese Players Out of India (and Make a Fortune in the Process)(The 5 Minute Wrapup)

Aug 17, 2017

A small-cap Indian company with high-return potential and blue-chip-like stability is set to supplant the Chinese players in this niche segment.

The Most Important Innovation in Finance Since Gold Coins(Vivek Kaul's Diary)

Aug 10, 2017

Bill connects the dots...between money and growth, real money and real resources, gold and cryptocurrencies...and between gold, cryptocurrencies, and time.

Signs of Life in the India VIX(Daily Profit Hunter)

Aug 12, 2017

The India VIX is up 36% in the last week. Fear has gone up but is still low by historical standards.

Bitcoin Continues Stellar Rise(Chart Of The Day)

Aug 10, 2017

Bitcoin hits an all-time high, is there more upside left?

5 Steps To Become Financially Independent(Outside View)

Aug 16, 2017

Ensure your financial Independence, and pledge to start the journey towards financial freedom today!

More

Become A Smarter Investor In
Just 5 Minutes

Multibagger Stocks Guide 2017
Get our special report, Multibagger Stocks Guide (2017 Edition) Now!
We will never sell or rent your email id.
Please read our Terms

SUN PHARMA SHARE PRICE


Aug 23, 2017 10:07 AM

TRACK SUN PHARMA

  • Track your investment in SUN PHARMA with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

COMPARE SUN PHARMA WITH

MARKET STATS